Accutar Biotech Stock
HealthTechLooking to sell Accutar Biotech stock or options?
Eligible for:
Charitable Exchange Fund
Accutar Biotech is a developer of bio-pharmaceutical technology aimed at speeding up drug discovery. The company employs computational drug design coupled with wet-lab validation, providing tools for side-chain flexible mode ligand docking, virtual screening, and prediction of drug ADME properties. This approach allows researchers to significantly cut down the time and expense typically associated with traditional drug discovery processes.
Investors Include:
Hedosophia, CMS Ventures, Karista (Paris), YITU, Mirae Asset Capital, 5Y Capital, Yunfeng Capital, 3W Partners Capital, Newton BioCapital, Primavera Capital Group, CDH Investments, ZhenFund, IDG Capital, Primavera Venture Partners, Coatue Management.